DoD Peer Reviewed Medical Technology/Therapeutic Development Award | Apply Online

FAQs: DoD Peer Reviewed Medical Technology/Therapeutic Development Award (PRMRP TTDA)

1) What is the PRMRP TTDA grant opportunity?

The DoD Peer Reviewed Medical Technology/Therapeutic Development Award (PRMRP TTDA) is a Department of Defense funding opportunity intended to move strong preclinical research results toward real-world medical products. The focus is on translation and product development rather than basic discovery.

2) What is the main goal of this award?

The main goal is to take promising preclinical findings and advance them into something that can be used in clinical settings to support prevention, detection, diagnosis, treatment, or improvements in quality of life.

3) Is this award meant for basic research or discovery science?

No. The emphasis is firmly on translation and product development, not on basic discovery or exploratory research.

4) What types of outcomes are expected from funded projects?

Projects are expected to generate a defined deliverable that is positioned for the next step toward real clinical impact. The intent is to move beyond simply generating additional exploratory data and instead advance a product toward clinical evaluation or deployment.

5) What does "product-driven" mean in the context of this award?

"Product-driven" means the proposed work should be oriented around developing a specific product or deliverable that can progress toward clinical use, rather than producing general knowledge without a clear path to application.

6) What counts as a "product" under the PRMRP TTDA?

A product can be a tangible medical technology such as a drug, biologic, or medical device. It can also be a knowledge-based deliverable, such as clinically actionable guidance that could influence standards of care.

7) What kinds of development activities does this award support?

The mechanism supports activities that bridge the gap between preclinical promise and clinical application. Examples described include refining the candidate technology, demonstrating performance and safety in relevant models, planning for regulatory pathways, and preparing for eventual clinical evaluation.

8) How important is alignment with PRMRP Topic Areas?

Alignment is required to be competitive. The work must align with at least one of the Congressionally directed FY15 Peer Reviewed Medical Research Program (PRMRP) Topic Areas.

9) Who is the research expected to benefit?

The project should clearly address health needs relevant to military Service members, Veterans, and/or other military beneficiaries.

10) What is a transition plan, and is it required?

A transition plan is required and is central to the program's intent. It must explain how the product will move forward after the PRMRP award period ends.

11) What should the transition plan include?

The transition plan should describe the next development milestone (for example, initiating clinical trials, scaling manufacturing, regulatory submissions, or preparing for distribution and adoption) and identify potential resources and funding to support that next phase.

12) What are reviewers looking for in the transition plan?

Reviewers are looking for a credible pathway showing the project is not a dead end at the conclusion of the grant, but is set up to continue into clinical testing or deployment in military or civilian healthcare markets.

13) What is the Funding Opportunity Number (FON) for this program?

The Funding Opportunity Number listed is W81XWH-15-PRMRP-TTDA.

14) Which DoD office administered this opportunity?

The opportunity was offered by the Department of the Army through the U.S. Army Medical Research Acquisition Activity (USAMRAA).

15) What is the CFDA number associated with this opportunity?

The program was classified under CFDA 12.420 (Military Medical Research and Development).

16) What funding instruments were used for awards under this opportunity?

The instrument types listed include cooperative agreement and grant.

17) What activity category does this funding fall under?

The activity category is science and technology and other research and development.

18) How much total funding was estimated to be available?

The estimated total funding available was $27,000,000.

19) How many awards were expected?

The opportunity expected approximately 10 awards.

20) Was cost sharing or matching required?

No. The announcement indicated there was no cost-sharing or matching requirement.

21) Who was eligible to apply?

Eligibility was described as unrestricted, meaning it was broadly open to different entity types, subject to any additional eligibility clarifications in the full announcement.

22) When was the opportunity posted?

The opportunity was posted on April 17, 2015.

23) What were the application deadlines?

The original and final closing date listed was October 15, 2015.

24) Is this opportunity still open?

No. The listing indicates it was archived on November 14, 2015, and the final closing date was October 15, 2015.

25) Who can applicants contact for help accessing the full announcement?

For help accessing the full announcement, the contact provided was the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.